Paper42495375
Research Progress on ROS Scavenging and Responsive Materials for Biomedical Applications.
Wang H and 7 others. ACS Omega, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Research Progress on ROS Scavenging and Responsive Materials for Biomedical Applications. Papers, record 42495375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42495375
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Research Progress on ROS Scavenging and Responsive Materials for Biomedical Applications.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References123
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40756364 | Mn3O4 nanozyme-based anti-inflammatory therapy modulates microglial phenotype by downregulating TLR4/NOX2 expression and further alleviates Alzheimer's disease pathology. | Theranostics | 2025 | https://conductscience.org/library/papers/40756364 | PubMed |
| 2 | 22747065 | Dye/peroxalate aggregated nanoparticles with enhanced and tunable chemiluminescence for biomedical imaging of hydrogen peroxide. | ACS Nano | 2012 | https://conductscience.org/library/papers/22747065 | PubMed |
| 3 | 41727272 | A mitochondria-targeted nanoantioxidant restores alveolar bone homeostasis in periodontitis by quenching ROS and suppressing the cGAS-STING pathway. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41727272 | PubMed |
| 4 | 38888130 | Targeted Modulation of Redox and Immune Homeostasis in Acute Lung Injury Using a Thioether-Functionalized Dendrimer. | Small | 2024 | https://conductscience.org/library/papers/38888130 | PubMed |
| 5 | 31115493 | Mitochondrial electron transport chain, ROS generation and uncoupling (Review). | Int J Mol Med | 2019 | https://conductscience.org/library/papers/31115493 | PubMed |
| 6 | 38778401 | Mild hyperthermia enhanced synergistic uric acid degradation and multiple ROS elimination for an effective acute gout therapy. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38778401 | PubMed |
| 7 | 37884805 | Targeting ROS production through inhibition of NADPH oxidases. | Nat Chem Biol | 2023 | https://conductscience.org/library/papers/37884805 | PubMed |
| 8 | 32231263 | Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/32231263 | PubMed |
| 9 | 39905851 | Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery. | J Mater Chem B | 2025 | https://conductscience.org/library/papers/39905851 | PubMed |
| 10 | 41698122 | Dual-Target ROS-Driven Spatiotemporal Senolysis for Vascular Repair and Immune Microenvironment Reprogramming in the Treatment of Ocular Fundus Neovascularization. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41698122 | PubMed |
| 11 | 33035856 | In vitro and in situ abrogation of biofilm formation in E. coli by vitamin C through ROS generation, disruption of quorum sensing and exopolysaccharide production. | Food Chem | 2021 | https://conductscience.org/library/papers/33035856 | PubMed |
| 12 | 34246260 | Fe3O4@Pt nanoparticles to enable combinational electrodynamic/chemodynamic therapy. | J Nanobiotechnology | 2021 | https://conductscience.org/library/papers/34246260 | PubMed |
| 13 | 41487054 | ROS-Responsive Wedelolactone Hydrogel Promotes Intervertebral Disc Repair by Disrupting the NF-κB-LCN2 Inflammatory Feedback Loop. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41487054 | PubMed |
| 14 | 36975358 | Advances of Mussel-Inspired Nanocomposite Hydrogels in Biomedical Applications. | Biomimetics (Basel) | 2023 | https://conductscience.org/library/papers/36975358 | PubMed |
| 15 | 40528838 | Synergistic ROS/enzyme dual-responsive oral drug delivery system: A novel multi-mechanistic platform for spatiotemporal control and overcoming drug resistance in colorectal cancer therapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40528838 | PubMed |
| 16 | 35987352 | Mitochondria-targeted nanozymes eliminate oxidative damage in retinal neovascularization disease. | J Control Release | 2022 | https://conductscience.org/library/papers/35987352 | PubMed |
| 17 | 34194012 | Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/34194012 | PubMed |
| 18 | 40391612 | ROS-Responsive Hydrogel Delivering METRNL Enhances Bone Regeneration via Dual Stem Cell Homing and Vasculogenesis Activation. | Adv Healthc Mater | 2025 | https://conductscience.org/library/papers/40391612 | PubMed |
| 19 | 30973011 | Reactive Oxygen Species (ROS)-Based Nanomedicine. | Chem Rev | 2019 | https://conductscience.org/library/papers/30973011 | PubMed |
| 20 | 41738076 | Nature-Inspired Surface Modification Strategy Reverses the Autophagic Flux Impairment of Mitochondrial Transplantation for Attenuating Ischemic Strokes. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41738076 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42495375
GET https://conductscience.org/api/papers/v1/42495375/references?page=2